About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Artificial Intelligence Helps Improve Treatment for Brain Tumor

by Colleen Fleiss on October 29, 2020 at 6:09 AM
Font : A-A+

Artificial Intelligence Helps Improve Treatment for Brain Tumor

In patients with glioblastoma (brain tumor) artificial intelligence measures the amount of muscle to help improve prognosis and treatment, said researchers.

Dr Ella Mi, a clinical research fellow at Imperial College London (UK) will tell the NCRI Virtual Showcase, that using deep learning (artificial intelligence) to evaluate MRI brain scans of a muscle in the head was as accurate and reliable as a trained person, and was considerably quicker.

Advertisement


Dr Mi said: "Finding a better way to assess patients' physical condition, general well-being and ability to carry out everyday activities is important in glioblastoma, and indeed in many cancers, because, at present, it's often evaluated subjectively, resulting in inaccuracy and a high degree of variability depending on who is looking at it. So indicators that can be assessed objectively, such as measures of sarcopenia, are needed."

Dr Mi and her colleagues from the Computational Oncology Group at Imperial, led by Dr Matthew Williams, looked at 152 MRI brain scans belonging to 45 patients from two different data sources who were diagnosed with glioblastoma between January 2015 and May 2018.
Advertisement

The brain scans taken from brain tumor patients, looked at the head's cross-sections. Researchers focused on the temporalis muscle. Temporalis, the broad, fan-shaped muscles on either side of the head that are used for chewing food - which has previously been identified as a good way to estimate skeletal muscle mass in the body.

"We realised that sarcopenia could be identified by quantifying muscle in cross-sectional imaging that cancer patients routinely undergo. This would allow for opportunistic screening of sarcopenia as part of cancer care without additional scanning time, radiation dose or cost," said Dr Mi.

Cross-sectional area (CSA) was a significant predictor of overall and progression-free survival. Patients with high CSA had around 60% reduction in death risk and 75% reduction in risk of disease progression compared to patients with low CSA.

Dr. Mi said: "To our knowledge, this is the first study, in any cancer, to apply deep learning to muscle segmentation and quantification for sarcopenia assessment, and to demonstrate significant associations with clinical outcomes. We are the first to show that this measurement of sarcopenia, generated automatically from routine imaging is sufficiently accurate and reliable to be a useful prognostic marker in cancer, while taking substantially less time than trained humans."

"We show that higher temporalis muscle area before surgery, chemotherapy or radiotherapy is predictive of significantly longer overall and progression-free survival. This has the potential to improve prognostic estimates and could be used to plan treatments. For instance, previous evidence has shown that frail patients might benefit from shorter courses of radiotherapy, or chemotherapy with temozolomide alone. It could also guide therapeutic interventions for muscle preservation, including nutritional support, exercise therapy and drugs."

The research by Ella Mi and her colleagues applied artificial intelligence/deep learning in cancer which is particularly aggressive and difficult to treat successfully in order to select the best treatment approach.

"At this stage their findings show that there is an association between the temporalis muscle size and a patient's frailty and how their disease progresses. The results do not show that the muscle area actually causes the change in patients' outcomes. The findings deserve study in a larger group of patients to take account of factors such as changes to the muscle caused by other factors, including surgery or radiotherapy," said Professor David Harrison, who is Professor of Pathology at the University of St Andrews and chair of the NCRI Cellular Molecular Pathology Initiative.

Glioblastoma Facts and Figures
  • It is an aggressive brain tumor that is very difficult to treat.
  • Average survival after diagnosis is 12-18 months.
  • Accounts for 52% of all primary brain tumors.
  • Occurs in adults between the ages 45 and 70.
Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Parkinsons Disease Parkinsons Disease Surgical Treatment Brain Tumor Brain Tumors Brain Tumor Markers For Cancer Diagnosis and Prognosis Brain Facts Ataxia Intellectual disability Language Areas in The Brain 

Recommended Reading
Artificial intelligence in Healthcare
Artificial intelligence (AI) in healthcare is the discipline using data intensive computer based ......
Glioblastoma Multiforme
Glioblastomas are tumors that arise from astrocytes that make up the supportive tissue of the ......
Test Your Knowledge on Artificial Intelligence
Artificial intelligence (AI) or machine intelligence refers to the intelligence displayed by ......
Understanding Brain Death - Animation
Interactive section of Medindia helps us in better understanding of Brain Death...
Ataxia
Ataxia affects coordination. Gait becomes unstable and the patient loses balance. The cerebellum or ...
Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors a...
Intellectual disability
Intellectual disability is a developmental delay that is significantly below average compared to pee...
Language Areas in The Brain
The mechanism of how human brain processes the language to express and comprehend the verbal, writte...
Parkinsons Disease
Parkinson’s disease is a neurodegenerative disease caused by progressive dopamine brain cells loss. ...
Tumor Markers For Cancer Diagnosis and Prognosis
An ideal tumor marker for a cancer should be specific to that cancer and not generate false positive...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use